Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LifeStance Health (LFST) EBIT (2020 - 2025)

LifeStance Health (LFST) has disclosed EBIT for 6 consecutive years, with -$3.5 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 116.86% to -$3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 million through Dec 2025, up 121.46% year-over-year, with the annual reading at $2.6 million for FY2025, 121.46% up from the prior year.
  • EBIT for Q4 2025 was -$3.5 million at LifeStance Health, down from $7.4 million in the prior quarter.
  • The five-year high for EBIT was $102.6 million in Q4 2021, with the low at -$124.7 million in Q3 2021.
  • Average EBIT over 5 years is -$23.9 million, with a median of -$24.5 million recorded in 2023.
  • The sharpest move saw EBIT tumbled 45335.58% in 2021, then skyrocketed 15665.96% in 2025.
  • Over 5 years, EBIT stood at $102.6 million in 2021, then plummeted by 144.83% to -$46.0 million in 2022, then rose by 29.86% to -$32.3 million in 2023, then skyrocketed by 163.75% to $20.6 million in 2024, then tumbled by 116.86% to -$3.5 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$3.5 million, $7.4 million, and -$2.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.